Saturday 17 October 2026
Export IMRN’s income statement to Excel — free account
IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.
0.98
0.05
−4.85%
Follow IMRN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 4.47 | 5.15 | 2.23 | 1.55 | 2.32 | 1.39 | 1.48 | 1.59 | 0.68 | 0.68 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 16.34 | 16.70 | 8.46 | 28.99 | 9.23 | 4.40 | 3.21 | 5.96 | 2.48 | 1.99 | |||||
| People | |||||||||||||||
| People | Employees | 7 | 5 | 6 | 5 | 4 | 5 | 6 | 7 | 7 | 7 | ||||
| Revenue/emp, $m | 0.15 | 0.29 | 0.28 | 0.34 | 0.03 | 0.11 | 0.20 | 0.46 | 0.67 | 0.75 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 3 | 5 | 5 | ||||
| Gross margin, % | 75.82 | 77.28 | 72.05 | 72.65 | 65.01 | 68.42 | 72.54 | 68.06 | 65.39 | 64.50 | |||||
| EBT | (5) | (2) | (3) | (2) | (6) | (2) | (3) | (5) | (3) | (2) | |||||
| EBT margin, % | (487.34) | (163.38) | (194.04) | (116.23) | (5,752.89) | (373.05) | (209.82) | (141.49) | (71.58) | (47.71) | |||||
| Net income | (5) | 0 | (3) | (2) | (6) | (2) | (3) | (5) | (3) | (2) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.40 | 0.43 | 0.47 | 0.38 | 0.02 | 0.10 | 0.21 | 0.56 | 0.82 | 0.70 | ||||
| Earnings | (1.58) | (0.71) | (0.92) | (0.45) | (1.17) | (0.36) | (0.45) | (0.80) | (0.59) | (0.37) | |||||
| Cash flow | (2.00) | (0.82) | (0.36) | (0.48) | (0.55) | (0.40) | (0.31) | (0.68) | (0.69) | (0.30) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (2.00) | (0.82) | (0.36) | (0.48) | (0.55) | (0.40) | (0.31) | (0.68) | (0.69) | (0.30) | |||||
| Book value | 1.87 | 1.96 | 1.45 | 0.86 | 3.50 | 2.96 | 2.32 | 1.46 | 0.91 | 1.02 | |||||
| Shares, m | 3 | 3 | 4 | 4 | 6 | 6 | 6 | 6 | 6 | 7 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | 0.00 | 0.00 | 0.00 | (0.63) | (10.00) | (24.73) | (7.30) | (4.35) | (1.01) | (3.47) | |||||
| EV/FCF | 0.00 | 0.00 | 0.54 | 0.45 | 2.27 | 1.77 | 1.99 | 1.00 | 0.15 | 0.58 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (5) | (3) | (1) | (2) | (3) | (2) | (2) | (4) | (4) | (2) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | |||||
| Free cash flow | (5) | (3) | (1) | (2) | (3) | (2) | (2) | (4) | (4) | (2) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 5 | 5 | 4 | 3 | 18 | 16 | 12 | 8 | 5 | 8 | ||||
| Total debt | 0 | — | — | 0 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | (3) | (4) | (4) | (2) | (19) | (16) | (13) | (8) | (2) | (6) | |||||
| Shareholders’ equity | 5 | 7 | 5 | 4 | 19 | 17 | 13 | 8 | 5 | 8 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (164.22) | (34.81) | (49.86) | (38.21) | (51.40) | (10.83) | (15.53) | (36.39) | (40.31) | (32.26) | ||||
| ROIC | (153.23) | (47.94) | (129.77) | (76.44) | (618.08) | (168.08) | (357.94) | (547.06) | (80.60) | (146.14) | |||||
| ROE | (118.87) | (40.60) | (56.16) | (43.45) | (54.15) | (11.45) | (16.98) | (42.24) | (49.82) | (39.02) | |||||
Negative figures in brackets.
Fiscal years to Jun 2026 · fundamentals updated 6 Oct 2026
Charts ten years each
IMMURON vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NKGN NKGen Biotech, Inc. | $8.8M | — (loss-making) | — | — | n/m | +28.68% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CSCIF COSCIENS Biopharma Inc. | $8.6M | 1.0× | — | +30.04% (above 0%: growing) | n/m | +113.30% (above 0%: growing) | 55.27% | 13.43% | Compare |
| IMRN IMMURON | $8.3M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | |
| ADIL Adial Pharmaceuticals, Inc. | $8.3M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $8.2M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| SNTI Senti Biosciences, Inc. | $8.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $8.1M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| XTLB XTL Biopharmaceuticals Ltd. | $8.1M | — (loss-making) | — | −39.32% (below 0%: shrinking) | n/m | +46.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $8.0M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| Median of peers | $8.2M | — | — | −39.32% | — | +10.60% | 76.01% | 0.00% |
IMMURON (IMRN) key facts
- Strength: IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025.
- IMMURON (IMRN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, IMRN traded at $0.98, a market capitalization of $8.3 million.
- Return on equity was −39.0% and debt-to-equity 0.00.
- Its Piotroski F-score is 5 out of 9 for fiscal 2026.